Impact of metabolic syndrome on the risk of cardiovascular disease mortality in the united states and in Japan

Longjian Liu, Katsuyuki Miura, Akira Fujiyoshi, Aya Kadota, Naoko Miyagawa, Yasuyuki Nakamura, Takayoshi Ohkubo, Akira Okayama, Tomonori Okamura, Hirotsugu Ueshima

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The United States has a higher prevalence of metabolic syndrome (MS) and cardiovascular disease (CVD) mortality than Japan, but it is unknown how much of the difference in MS accounts for the mortality difference. The aim of this study was to examine the impact of MS on the excess CVD mortality in the United States compared with that in Japan. Data from the United States Third National Health and Nutrition Examination Survey (NHANES III; n = 12,561) and the Japanese National Integrated Project for Prospective Observation of Noncommunicable Disease and Its Trends in Aged (NIPPON DATA; n = 7,453) were analyzed. MS was defined as ≥3 of 5 risk factors (obesity, high blood pressure, decreased high-density lipoprotein cholesterol, elevated glycosylated hemoglobin, and elevated triglycerides). The results show that after a median of 13.8 years of follow-up in the United States, 1,683 patients died from CVD (11.75 per 1,000 person-years), and after a median of 15 years of follow-up in Japan, 369 patients died from CVD (3.56 per 1,000 person-years). The age-adjusted prevalence of MS was 26.7% in the United States and 19.3% in Japan. Of 5 MS factors, obesity, high blood pressure, elevated triglycerides, and glycosylated hemoglobin in the United States, and high blood pressure and elevated glycosylated hemoglobin in Japan were significant risk factors for CVD mortality. Estimates of 13.3% and 44% of the excess CVD mortality for the United States could be explained by the higher prevalence of MS and MS plus baseline CVD history than in Japan. In conclusion, the present study is the first to quantitatively demonstrate that MS and MS plus baseline CVD history may significantly contribute to the explanation of excess CVD mortality in the United States compared with Japan.

Original languageEnglish
Pages (from-to)84-89
Number of pages6
JournalAmerican Journal of Cardiology
Volume113
Issue number1
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Japan
Cardiovascular Diseases
Mortality
Glycosylated Hemoglobin A
Nutrition Surveys
Hypertension
Triglycerides
Obesity
Metabolic Diseases
HDL Cholesterol
Observation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Impact of metabolic syndrome on the risk of cardiovascular disease mortality in the united states and in Japan. / Liu, Longjian; Miura, Katsuyuki; Fujiyoshi, Akira; Kadota, Aya; Miyagawa, Naoko; Nakamura, Yasuyuki; Ohkubo, Takayoshi; Okayama, Akira; Okamura, Tomonori; Ueshima, Hirotsugu.

In: American Journal of Cardiology, Vol. 113, No. 1, 01.01.2014, p. 84-89.

Research output: Contribution to journalArticle

Liu, L, Miura, K, Fujiyoshi, A, Kadota, A, Miyagawa, N, Nakamura, Y, Ohkubo, T, Okayama, A, Okamura, T & Ueshima, H 2014, 'Impact of metabolic syndrome on the risk of cardiovascular disease mortality in the united states and in Japan', American Journal of Cardiology, vol. 113, no. 1, pp. 84-89. https://doi.org/10.1016/j.amjcard.2013.08.042
Liu, Longjian ; Miura, Katsuyuki ; Fujiyoshi, Akira ; Kadota, Aya ; Miyagawa, Naoko ; Nakamura, Yasuyuki ; Ohkubo, Takayoshi ; Okayama, Akira ; Okamura, Tomonori ; Ueshima, Hirotsugu. / Impact of metabolic syndrome on the risk of cardiovascular disease mortality in the united states and in Japan. In: American Journal of Cardiology. 2014 ; Vol. 113, No. 1. pp. 84-89.
@article{ac0ce004f035439aa03e0745745c9aa2,
title = "Impact of metabolic syndrome on the risk of cardiovascular disease mortality in the united states and in Japan",
abstract = "The United States has a higher prevalence of metabolic syndrome (MS) and cardiovascular disease (CVD) mortality than Japan, but it is unknown how much of the difference in MS accounts for the mortality difference. The aim of this study was to examine the impact of MS on the excess CVD mortality in the United States compared with that in Japan. Data from the United States Third National Health and Nutrition Examination Survey (NHANES III; n = 12,561) and the Japanese National Integrated Project for Prospective Observation of Noncommunicable Disease and Its Trends in Aged (NIPPON DATA; n = 7,453) were analyzed. MS was defined as ≥3 of 5 risk factors (obesity, high blood pressure, decreased high-density lipoprotein cholesterol, elevated glycosylated hemoglobin, and elevated triglycerides). The results show that after a median of 13.8 years of follow-up in the United States, 1,683 patients died from CVD (11.75 per 1,000 person-years), and after a median of 15 years of follow-up in Japan, 369 patients died from CVD (3.56 per 1,000 person-years). The age-adjusted prevalence of MS was 26.7{\%} in the United States and 19.3{\%} in Japan. Of 5 MS factors, obesity, high blood pressure, elevated triglycerides, and glycosylated hemoglobin in the United States, and high blood pressure and elevated glycosylated hemoglobin in Japan were significant risk factors for CVD mortality. Estimates of 13.3{\%} and 44{\%} of the excess CVD mortality for the United States could be explained by the higher prevalence of MS and MS plus baseline CVD history than in Japan. In conclusion, the present study is the first to quantitatively demonstrate that MS and MS plus baseline CVD history may significantly contribute to the explanation of excess CVD mortality in the United States compared with Japan.",
author = "Longjian Liu and Katsuyuki Miura and Akira Fujiyoshi and Aya Kadota and Naoko Miyagawa and Yasuyuki Nakamura and Takayoshi Ohkubo and Akira Okayama and Tomonori Okamura and Hirotsugu Ueshima",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.amjcard.2013.08.042",
language = "English",
volume = "113",
pages = "84--89",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Impact of metabolic syndrome on the risk of cardiovascular disease mortality in the united states and in Japan

AU - Liu, Longjian

AU - Miura, Katsuyuki

AU - Fujiyoshi, Akira

AU - Kadota, Aya

AU - Miyagawa, Naoko

AU - Nakamura, Yasuyuki

AU - Ohkubo, Takayoshi

AU - Okayama, Akira

AU - Okamura, Tomonori

AU - Ueshima, Hirotsugu

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The United States has a higher prevalence of metabolic syndrome (MS) and cardiovascular disease (CVD) mortality than Japan, but it is unknown how much of the difference in MS accounts for the mortality difference. The aim of this study was to examine the impact of MS on the excess CVD mortality in the United States compared with that in Japan. Data from the United States Third National Health and Nutrition Examination Survey (NHANES III; n = 12,561) and the Japanese National Integrated Project for Prospective Observation of Noncommunicable Disease and Its Trends in Aged (NIPPON DATA; n = 7,453) were analyzed. MS was defined as ≥3 of 5 risk factors (obesity, high blood pressure, decreased high-density lipoprotein cholesterol, elevated glycosylated hemoglobin, and elevated triglycerides). The results show that after a median of 13.8 years of follow-up in the United States, 1,683 patients died from CVD (11.75 per 1,000 person-years), and after a median of 15 years of follow-up in Japan, 369 patients died from CVD (3.56 per 1,000 person-years). The age-adjusted prevalence of MS was 26.7% in the United States and 19.3% in Japan. Of 5 MS factors, obesity, high blood pressure, elevated triglycerides, and glycosylated hemoglobin in the United States, and high blood pressure and elevated glycosylated hemoglobin in Japan were significant risk factors for CVD mortality. Estimates of 13.3% and 44% of the excess CVD mortality for the United States could be explained by the higher prevalence of MS and MS plus baseline CVD history than in Japan. In conclusion, the present study is the first to quantitatively demonstrate that MS and MS plus baseline CVD history may significantly contribute to the explanation of excess CVD mortality in the United States compared with Japan.

AB - The United States has a higher prevalence of metabolic syndrome (MS) and cardiovascular disease (CVD) mortality than Japan, but it is unknown how much of the difference in MS accounts for the mortality difference. The aim of this study was to examine the impact of MS on the excess CVD mortality in the United States compared with that in Japan. Data from the United States Third National Health and Nutrition Examination Survey (NHANES III; n = 12,561) and the Japanese National Integrated Project for Prospective Observation of Noncommunicable Disease and Its Trends in Aged (NIPPON DATA; n = 7,453) were analyzed. MS was defined as ≥3 of 5 risk factors (obesity, high blood pressure, decreased high-density lipoprotein cholesterol, elevated glycosylated hemoglobin, and elevated triglycerides). The results show that after a median of 13.8 years of follow-up in the United States, 1,683 patients died from CVD (11.75 per 1,000 person-years), and after a median of 15 years of follow-up in Japan, 369 patients died from CVD (3.56 per 1,000 person-years). The age-adjusted prevalence of MS was 26.7% in the United States and 19.3% in Japan. Of 5 MS factors, obesity, high blood pressure, elevated triglycerides, and glycosylated hemoglobin in the United States, and high blood pressure and elevated glycosylated hemoglobin in Japan were significant risk factors for CVD mortality. Estimates of 13.3% and 44% of the excess CVD mortality for the United States could be explained by the higher prevalence of MS and MS plus baseline CVD history than in Japan. In conclusion, the present study is the first to quantitatively demonstrate that MS and MS plus baseline CVD history may significantly contribute to the explanation of excess CVD mortality in the United States compared with Japan.

UR - http://www.scopus.com/inward/record.url?scp=84890428803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890428803&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2013.08.042

DO - 10.1016/j.amjcard.2013.08.042

M3 - Article

VL - 113

SP - 84

EP - 89

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 1

ER -